Perspective Therapeutics, Inc. (CATX) Diversifiers

Equity · Currency in USD · Last updated Jul 25, 2026

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that develops and commercializes precision targeted alpha therapies to treat cancer in the United States. Its lead candidates include VMT-alpha-NET, in Phase 1/2a trials for somatostatin receptor type 2-expressing neuroendocrine tumors; VMT01, in Phase 1/2a trials for melanocortin 1 receptor positive metastatic melanoma; and PSV359, targeting fibroblast activation protein alpha. The company has a clinical trial collaboration with Bristol Myers Squibb. Formerly known as Isoray, Inc., it was founded in 2004 and is headquartered in Seattle, Washington.

Looking to balance out your exposure to CATX? The ETFs below have the lowest correlation with CATX — they tend to move on their own, which can help reduce risk when CATX drops. The stock ideas table highlights individual companies that behave independently from CATX.

No Diversifiers Found for CATX

We do not have enough correlation history to rank diversifiers for this symbol yet.

Diversification Analysis

Build a portfolio that complements CATX

Add CATX to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.

Analyze a portfolio with CATX